LEXICON PHARMACEUTICALS, INC.LXRX

LEXICON PHARMACEUTICALS, INC. Fair Value Disclosure

10-KFiled Mar 5, 20262 min read
Fair Value Measurements
 
The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:
 
•Level 1 – quoted prices in active markets for identical assets, which include U.S. treasury securities
 
•Level 2 – other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which include corporate debt securities
 
•Level 3 – significant unobservable inputs

     The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following tables provide the fair value measurements of applicable Company assets that
are measured at fair value on a recurring basis according to the fair value levels defined above as of December 31, 2025 and 2024. There were no transfers between Level 1 and Level 2 during the periods presented.

 
 Assets at Fair Value
As of December 31, 2025
 Level 1Level 2Level 3Total
 (in thousands)
Cash and cash equivalents$34,326 $— $— $34,326 
Short-term investments39,026 22,878 — 61,904 
Restricted cash29,000 — — 29,000 
Total cash and cash equivalents, short-term investments and restricted cash$102,352 $22,878 $— $125,230 

 Assets at Fair Value
As of December 31, 2024
 Level 1Level 2Level 3Total
 (in thousands)
Cash and cash equivalents$66,656 $— $— $66,656 
Short-term investments127,990 43,311 — 171,301 
Restricted cash— — — — 
Total cash and cash equivalents, short-term investments and restricted cash$194,646 $43,311 $— $237,957 
The carrying amount of prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. The fair value of the Oxford Term Loans (see Note 9) is determined under Level 2 in the fair value hierarchy and approximates carrying value as the loans bear interest at a rate that approximates prevailing market rates for instruments with similar characteristics.
Free Sentinel

Want the next LEXICON PHARMACEUTICALS, INC. fair value disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment LEXICON PHARMACEUTICALS, INC.'s next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

Historical Timeline

Fiscal YearFiled
2025Mar 5, 2026Showing above
2024Mar 7, 2025
2023Mar 25, 2024
2022Mar 3, 2023
2021Mar 10, 2022
2020Mar 12, 2021
2019Mar 12, 2020
2018Mar 15, 2019
2017Mar 1, 2018
2016Mar 6, 2017
2015Mar 11, 2016

About Fair Value Disclosures

Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.

Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.

Other Available Disclosures

Income TaxesRevenueEarnings Per SharePP&EGoodwill & IntangiblesSegmentsDebtCommitmentsStock CompensationNew StandardsPay vs Performance